ArticleAJOG global reports2026
Pharmacologic cervical ripening strategies and time-related outcomes: a community hospital cohort study.
Article in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacologic cervical ripening is a primary determinant of labor induction efficiency, yet practice-based data from community hospitals remain limited.
objectiveTo compare time-related outcomes-specifically time to delivery and hospital length of stay-among inductions using misoprostol or dinoprostone, while examining the influence of parity. STUDY
designThis retrospective cohort study at an urban community hospital (2022-2023) analyzed inductions utilizing only pharmacologic ripening. Exclusion criteria included prolonged antepartum admission, premature rupture of membranes, intrauterine fetal demise, cervical balloon use, or use of both misoprostol and dinoprostone. Patients were categorized by agent: misoprostol (n=188) or dinoprostone (n=477). Primary outcome was time to delivery, with total hospital length of stay also examined. Secondary outcomes included cesarean delivery and neonatal intensive care unit (NICU) admission. Subgroup analyses were performed for nulliparous and multiparous patients.
resultsIn the overall cohort, misoprostol was associated with a shorter time to delivery compared with dinoprostone (24.3 vs 28.6 hours;
conclusionIn this community hospital cohort, misoprostol was associated with shorter induction durations than dinoprostone, with efficiency gains primarily driven by outcomes in multiparous patients. These findings suggest that pharmacologic agent selection for cervical ripening can meaningfully influence obstetric workflow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.